We all know pill popping isn’t the answer when it comes to losing weight and keeping if off. But clinical trials with a new anti-obesity drug look promising. The drug, called rimonabant, was developed after scientists noticed that cannabis smokers often had increased appetites and frequently experienced the ‘munchies’.

They worked on the idea that if substances from cannabis called cannabinoids stimulated appetite, blocking the cannabinoid receptors in the brain might reduce appetite.

Furthermore, blocking these receptors might also help people to give up smoking as these receptors not only appear to be involved in controlling food intake, but also have a role to play in tobacco dependence.

Earlier trials with the drug, which works by blocking cannabinoid receptors in the brain, have already shown promising results. But now a new study published in medical journal The Lancet, confirms the drug can help with weight loss and reduce the risk factors associated with heart disease.

The drug is only suitable for people who have a body mass index of over 30 or over 27 if there are other health problems. This means someone who weighs 14st, may lose up to 20lb in a year by taking this drug. That’s good news, but let’s face it, most of us can achieve this – and a whole lot more – by dieting and exercising alone. Bottom line, even if this drug does get approved, it might help you lose some weight and improve your overall heart health – but it won’t make you skinny!

Rimonabant is the generic name for Acomplia and Zimulti. This medication can and does work on its own to bring your body weight down but, if you want the best results, you have to increase the amount of exercise you do and eat less. No-one has invented a “fat buster” medication. Even though Rimonabant is the best weight loss medication on the market, you have to make lifestyle changes if you want to make your dream of losing weight a permanent reality. Note the use of “permanent”. So many people start off with the best intentions and then give up. That means their weight is like a yo-yo. Up one month, down the next. This approach to weight loss is unhealthy. So treat today as New Year’s Day and make a Resolution to buy Rimonabant. Resolve that you will change your diet. Resolve that you will get off that couch (some of the time). Burning off the calories through exercise will give you the maximum effect. If you spend the money on Rimonabant, you owe it to yourself to get the best results.

Acomplia is a pharmaceutical grade anti-obesity medication, available by prescription only. I don’t think that it is even available (legally) in the USA, but it is being sold over in Europe. Now because Acomplia is not a dietary supplement, it only contains one ingredient. The main ingredient is Acomplia is a drug called Rimonabant. Rimonabant claims to help reduce your appetite and its success is contingent upon a healthy diet and exercise.

Acomplia Rimonabant (Zimulti) Ingredients

In Acomplia drug, Rimonabant is the active ingredient which works on the principle of an appetite suppressant. The CB-receptors in the body are responsible for regulating food intake of the body. Usage of Acomplia (Rimonabant) basically obstructs the functioning of these CB-1 receptors, thereby decreasing your appetite. This activity in turn leads to weight loss. A combination of proper diet and regular workout regime along with Acomplia drug (Rimonabant) can pave path for an effectual weight loss.

Generic Acomplia (rimonabant) Rimonabant is an anorectic anti-obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite. Generic Acomplia Rimonabant acts by obstructing the receptors, which control the food intake and energy expenditure. These receptors exist on cells in the body, including those related to weight gain. Thus resulting in reduced appetite. Acomplia (Rimonabant). This is the new weight loss, NON controlled medication, that many use as an alternative to Phentermine.

What Doctors Say About Acomplia

Here are some of the things being said about Acomplia by doctors.

“If there was a pill available that was safe, effective and made it easy to lose any weight at all, there would be a truly massive market.” Dr. Steve Bloom, researcher at Imperial College in London, quoted on June 28, 2006 by Bloomberg

“Acomplia’s been given to 13,000 people but you just don’t completely know what happens when you give it to a million.” Dr. Louis J. Aronne, New York Hospital - Cornell Medical Center, quoted on June 28, 2006 by Bloomberg

“Rimonabant shows a substantial weight reduction, and if that’s possible without side effects it could be promising. I have concerns about the idea you just buy a medocation and that’s it, buying weight reduction instead of changing lifestyle habits.” Dr.Otto Smiseth, a professor of medicine at University of Oslo, quoted on Aug. 29. 2004 by Bloomberg.

“We come up with new medocations on the drawing board all the time, but rarely do they work the way we think they will. This one did. I think the medocation has incredible potential.” Dr. Elbert Glover of West Virginia University Medical School quoted in the Aug. 14, 2004 issue of Newsweek.

Rimonabant Work the Same as Generic Acomplia?

With several mid-sized Indian pharmaceutical companies now selling a drug in India that they say is rimonabant, how likely is it that these drugs work exactly the same way as the Sanofi-Aventis drug Generic Acomplia? That, of course, is always the question when drug companies bring out a generic — an imitator of the innovator drug — when the original patent obtained by the drug’s developer expires. And regulators in the U.S. and Europe then have to decide whether the generic and the original are bioequivalent.In this case, the patent protection that Sanofi has for the drug it markets as Generic Acomplia in Europe and hopes to sell as Zimulti in the United States has many years to run in most of the world.

Generic Acomplia being sold today consists of film-coated tablets containing 20 mg of the rimonabant polymorphic form 2, and the European Medicines Agency said ‘bridging’ bioequivalence studies found the differences between these tablets and the hard pills “to be minor and of no clinical significance in the satisfactory performance of the marketed product.”

Sanofi-Aventis is still hopeful that Acomplia deit pill will be made available in the U.S. market after the approval by the U.S. Food and Drug Administration.
The chapter of acomplia in the U.S.market still is not closed for the Sanofi-Aventis.
Last month Sanofi pulled its application for the approval of Acomplia Diet Pill in the U.S. market . The FDA had voted against the approval of it by taking in consideration the issue of depression and suicidal thoughts as a side effect of acomplia weight loss pill.

A lot of time is lost in America which will be resulted in a profitable cost. The analyst had estimated that the acomplia weight loss pill could be a $5 billion drug and with out U.S market it is estimated that the diet pill for weight loss acomplia has total sales of more than $500 million worldwide.

In Europe the number of obese and overweight patients who takes diet pills for weight loss acomplia is more than 200,000 . The remaining handful of the patients live in other countries of the world. Sanofi-Aventis didn’t give no significance of approval for early sale in the United States.

FDA gives the signal of talking to Sanofi regarding the approval of Zimulti in United States as soon as the completion of additional data confirming the benefit risk profile of best pill for weight loss acomplia .

Acomplia, Diet pills for weight loss which has been approved in the European countries with a strong warning which can be helpful for FDA for the approval of it in United States.

Indian media pointed out that copies of acomplia diet pill are being sold at Indian pharmacies .The pill for weight loss can be obatained for as little as $3.60 for a month.

In May a half-dozen top respected pharmaceutical companies which includes Ranbaxy and Cipla had received an approval from Indian regulatory authorities to sell their own versions of rimonabant.

Acomplia/Zimulti which is developed by Sanofi-Aventis has been approved for sale in India in May but Sanofi-Aventis didn’t put acomplia diet pill in Indian market. Acomplia which is not approved for sale in United States but is sold in Europe for more than $100 per month.

The generic rimonabant which is sold in Indian market is entirely legal in India. The reverse-engineered version of acomplia which was patented before 1995 is permitted for sale in India but sale of this Indian version would not be legal in U.S., Europe or Canada.

The doctor says the overdosing of the acomplia diet pill and taken inappropriately may be harmful for the obese people.

 Rimonabant diet pill online

On March 9^th, the French drug company Sanofi-Synth�labo, announced the early results of two Phase III studies with their new drug they call �ACOMPLIA�� (rimonabant). Rimonabant is the first in a class of drugs called Selective CB1 Blockers. They report that overweight/obese patients lost weight over 12 months while improving their lipid and glucose profiles. Not only that, but smokers who had previously unsuccessfully tried to quit smoking, were able to quit in 10 weeks without the usual post cessation weight gain. The results of both the RIO-Lipids (Rimonabant In Obesity) and STRATUS-US (STudies with Rimonabant And Tobacco USe) trials were presented for the first time at the American College of Cardiology annual meeting in New Orleans, LA. Rimonabant phase III programs in obesity and smoking cessation are due to be completed at the end of 2004; the product is still non-approved for marketing.

The �CB� in CB1 stands for cannabinoid receptor type-1. This receptor is the primary receptor involved in the actions of cannabis (delta 9-THC). The cannabinoid system is involved in everything from sleep/wake cycle to sexual behavior. Not only will Rimonabant help you eat less, but it will also help you get up in the morning, stop smoking, and stop drinking. In essence, this drug takes away the brain�s �reward� after ingesting/inhaling most addictive substances (including sugary-fat) and/or behaviors.

Is this type of brave new drug good for us? I mean, is it better to use a drug to control others, and our selves, or is it better to struggle and fight until we grow stronger and are able to overcome our weaknesses?

Rimonabant diet pill 

To be honest, I used to feel that people who overate themselves into the hospital from obesity, diabetes, and related complications deserved what they got. After all, no one was forcing them to eat. They knew that they were making themselves sick by eating so much and exercising so little. Over the years however, I have had a change of heart.

After working with thousands of individuals to help them improve their health, whether it was by eating better, exercising, or using medications to lose weight, I have gotten to the point where it just seems better for some people to staple their stomachs or take mind altering drugs to get them to stop eating so much. After all, I�ve seen many obese people spend a great deal of time and money on the best trainers and dietitians and still not overcome their devastating eating habits. In the end, what does it accomplish to keep throwing �self control� at them when it obviously doesn�t work? After 10 years of struggling I would say nothing.

• Rimonabant pill

Write in and tell me what you think of the ever-increasing trend towards the use of medications to control our own behavior. I�ll share some of your responses to this question in the next newsletter. So if there is something you want a lot of people to hear, write to me at (bryan at hsnhst dot com). Sorry I can�t just write it out but the SPAM bots sniff out email addresses from the website and bombard me with junk …

We are living in an advanced world, which has changed its life style completely, and with change in life style many new complications have taken birth. Obesity is a disease, which has its lineage with modern life style. We are sustaining our lives in a hectic schedule where we don’t have time to pay proper attention to our body. Even when people caught in diseases like cold, fever etc. they hardly get time to take an appointment with the doctor. Obesity and problems related with it do not affect rapidly. They appear slowly and consequently till then people are ignorant about increasing size of their tummy.

One more habit which modern life style brings with it is dependence on junk food. Two minutes cooking or ready to eat eatables don’t have nutrients in a balanced amount. These foods are rich in fats and carbohydrates but deficient in vitamins, minerals and proteins. These foods give us excessive calories, which are accumulated in the body in the form of fat. This accumulation of fat beneath the skin provides us a bulky appearance.

Nature has provided us the capability of burning this accumulation of fat through proper physical work. An obese whenever burns fat through exercising; it is regained from excessive intake of calories. Therefore, it is essential for anyone who wants to loose weight to have control over his or her dietary habits. People generally find it difficult to have a control over their dietary habits because of adjustment of body to excessive amount of food intake.

For all such obese who are desperate to loose weight but find it difficult to have control over appetite, Acomplia (Rimonabant) can be a great help. Sanofi-Aventis of France recently launched this high efficacy diet suppressor in the European anti-obesity drug market. The sale of Acomplia firstly started in the UK where numerous obese have reduced weight successfully with its help. Sanofi-Aventis is planning to start the sale of this medication in other countries of Europe like Germany, Norway, Iceland etc. There are about 25 European countries where this medication can be sold. Sanofi-Aventis has got license in this regard by an agreement signed by 25 members of European Union. Sanofi-Aventis is planning to launch this drug in the US for which FDA approval is anticipated very soon.

As we all know that the main cause of obesity is overeating. If you are not satisfied with your balanced diet then definitely, you are pushing your body towards obesity and increasing unwanted weight to your body. Your body health is directly related to your satisfaction. So if you are not satisfied with your balanced diet then you will try to eat more food and after some times you gain extra body weight. In our busy life we have no time for doing exercise or yoga so we definitely eat more calories than our body burn in a day. Extra calories in your body convert to fats and hence we gain unwanted weight to our body every day.

For reducing weight you must balance your body intake calories and burn calories. According to weight loss experts your body must burn more calories than you take for living a healthy life. For reducing calories in your body you must eat less food and increase your physical activities like using of stairs instead of elevator. However these tasks are very difficult for you like increasing physical activities and controlling your self for overeating. So you should need other weight loss solutions and the answer for all your problem is Acomplia Riminabant diet pill.

Acomplia Rimonabant diet pills are UK approved prescription weight loss drugs. This weight loss drugs is especially for an obese patient of body mass index more than 28 or 30. The main task of Acomplia Rimonabant weight loss drug is that it can facilitate you in your endeavor of weight loss by blocking the CB-1 receptors, which regulate food intake of the body. This will help you to decreasing your appetite so that you eat less food and hence lose weight.

Acomplia weight loss medication is available in the strengths of 10mg and 20mg. The dosage of Acomplia is 20mg pill, which should be consumed with a glassful of water.

You can buy acomplia online on the net. But before starting Acomplia diet pill course you must read its side effects and precautions. The main side effects of acomplia rimonabant diet pills are headache, nausea and dizziness.

Buy Acomplia through an online order and lose weight by the generation of contentment. The delivery of an online order is made at your doorstep.

Buy Rimonabant From Europe

Acomplia Rimonabant has been approved as a new weight loss drug by European Union in all European countries. It can be bought online from the UK pharmacies, that also offer a free consultation required before Acomplia is prescribed. GetPharma ships in Europe, in Asia and other parts of the world except Germany and Norway.

Buy Rimonabant online - Unites States and Canada

For people in United States, Acomplia Rimonabant may be bought online from a famous U.K. Pharmacy that ships in Canada and United States - US . Acomplia is a legal to be consumed drug in Canada. The Pharmacy will give a free consultation required before Acomplia is prescribed. This U.K. Pharmacy makes the drugs available worldwide, including in United States, Germany or Norway !

  PARIS, Dec. 8 /PRNewswire-FirstCall/ — Sanofi-aventis announces that concerning the New Drug Application for rimonabant in the United States, the Food and Drug Administration has considered its October 26, 2006 resubmission to be a complete, class 2 response to the FDA February 17, 2006 action letter.

The user fee goal date is April 26, 2007.

About Rimonabant

Rimonabant is a first-in-class cannabinoid type 1 (CB1) receptor blocker discovered and developed by sanofi-aventis.

In Europe, rimonabant, known as ACOMPLIA(R) is approved as an adjunct to diet and exercise for the treatment of obese patients (BMI greater than or equal to 30kg/m2), or overweight patients (BMI>27kg/m2) with associated risk factors, such as type 2 diabetes or dyslipidaemia.

Rimonabant is currently commercialized in the United Kingdom, Germany, Denmark, Sweden, Finland, Norway, Ireland, Argentina and Austria.

About sanofi-aventis

Sanofi-aventis is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. Sanofi-aventis is listed in Paris and in New York .

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expect,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2005. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Acomplia(R) (Rimonabant) Recommended for Approval in the European Union

sanofi-aventis

PARIS, France, April 28, 2006 — Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant marketing authorisation in the European Union for ACOMPLIA(R) (rimonabant 20mg) for the following indication: ” As an adjunct to diet and exercise for the treatment of obese patients (BMI greater than or equal to 30kg/m2), or overweight patients (BMI > 27 kg/m2) with associated risk factors, such as type 2 diabetes or dyslipidemia (see section 5.1).” Section 5.1 of the Summary of Product Characteristics is the section of the labelling where detailed clinical study results supporting the indication are described. Importantly, statements in this section stipulate that half of the observed improvements in HbA1c, HDL cholesterol and triglycerides were beyond that expected from weight loss alone.

ACOMPLIA(R), a first-in-class selective CB1 blocker, has been discovered and developed by sanofi-aventis.

The CHMP, comprised of regulators from all European Union countries, gave its positive opinion following a timely one-year review of the ACOMPLIA(R) application. The recommendation to grant marketing authorization was based on the review of comprehensive efficacy and safety data, including data from the RIO clinical trial program which involved more than 6,600 patients worldwide, studied for up to two years, where it has been demonstrated that rimonabant 20mg/day significantly improved weight and waist circumference, HbA1c, HDL cholesterol and triglycerides.

“Obesity levels in the European Union have risen significantly in the past decade in the adult population, and this represents a serious public health concern. Specifically, those with abdominal obesity are at the greatest risk of developing type 2 diabetes and heart disease, due to the link between abdominal obesity and other risk factors [1],[2]” said Luc Van Gaal, M.D., Professor of Diabetology, Metabolism and Clinical Nutrition, Antwerp University Hospital, Belgium and Principal Investigator of the RIO Europe trial. “ACOMPLIA(R) is an innovative, first-in-class treatment which will offer physicians a new approach to managing multiple cardiometabolic risk factors in patients with abdominal obesity who have other conditions such as type 2 diabetes, or unhealthy lipids. We should only use this drug in such patients where there is a real medical need, and not in people who may seek to use it for cosmetic reasons.”